TransThera Sciences (Nanjing), Inc. Announces Completion of HK\$290 Million H Share Placement
TransThera Sciences (Nanjing), Inc. (Stock Code: 2617), a leading biopharmaceutical company headquartered in China, has successfully completed a major placement of new H shares under its general mandate. This strategic move is set to bolster the company’s financial position and support key development initiatives.
Key Points of the Announcement
- Completion of Placement: The company confirmed that all conditions outlined in the Placing Agreement were fulfilled, with completion occurring on April 21, 2026.
- Shares Placed: A total of 5,085,000 new H shares have been placed at a price of HK\$57.03 per share, raising gross proceeds of approximately HK\$290 million.
- Placees: The shares were allocated to not less than six professional, institutional, or other investors, all of whom are independent third parties. None of the placees became a substantial shareholder upon completion.
- Impact on Share Capital: The placement shares represent about 1.67% of existing issued H shares and 1.27% of the company’s total issued shares prior to completion. After the placement, H shares make up approximately 76.43% of the total share capital, while unlisted shares account for 23.57%.
Detailed Use of Proceeds
The net proceeds from the placement, after deducting commission and related costs, amount to approximately HK\$282.15 million (net issue price HK\$55.49 per share). The company has outlined a clear allocation plan for these funds:
- Research and Development (57% / HK\$160.83 million): Dedicated to advancing clinical development of the core product, Tinengotinib, for indications such as advanced-stage breast cancer, hepatocellular carcinoma, castration-resistant prostate cancer, and also the development of TT-00973.
- Manufacturing and Commercialization (33% / HK\$93.11 million): Focused on manufacturing Tinengotinib in China and supporting commercialization efforts, including building commercial teams and executing marketing activities.
- Working Capital and General Corporate Purposes (10% / HK\$28.21 million): To be used for the company’s general corporate needs and operational flexibility.
Shareholding Structure Post-Placement
| Class of Shares |
Pre-Placement (Shares) |
Pre-Placement (%) |
Post-Placement (Shares) |
Post-Placement (%) |
| Unlisted Shares (Core connected persons) |
50,259,832 |
12.60% |
50,259,832 |
12.44% |
| Unlisted Shares (Other) |
44,971,128 |
11.27% |
44,971,128 |
11.13% |
| Total Unlisted Shares |
95,230,960 |
23.87% |
95,230,960 |
23.57% |
| H Shares (Core connected persons) |
80,597,797 |
20.20% |
80,597,797 |
19.94% |
| H Shares (Placees) |
– |
– |
5,085,000 |
1.26% |
| H Shares (Other H shareholders) |
223,168,876 |
55.93% |
223,168,876 |
55.23% |
| Total H Shares |
303,766,673 |
76.13% |
308,851,673 |
76.43% |
| Total Shares |
398,997,633 |
100.00% |
404,082,633 |
100.00% |
Note: Core connected persons include Dr. Frank Wu’s beneficial holdings and interests through controlled corporations.
Key Information for Shareholders and Potential Price Sensitivity
- Significant Funding Secured: The successful placement and the resulting capital infusion will strengthen the company’s balance sheet and accelerate the development and commercialization of its lead drug candidates.
- Pipeline Advancements: The allocation of over half the net proceeds to R&D, especially for Tinengotinib, signals a strong commitment to bring innovative therapies to market, potentially increasing the company’s valuation as these assets progress through clinical stages.
- Share Dilution: The placement increases the total issued share capital by about 1.27%. While this represents some dilution, the anticipated value generated from successful R&D and commercialization activities may more than offset this in the medium to long term.
- Broader Shareholder Base: The introduction of new professional and institutional investors may enhance trading liquidity and market visibility for TransThera’s shares.
Board and Management Update
The Board of Directors remains unchanged, led by Dr. Frank Wu as Chairman and CEO, with a mix of executive, non-executive, and independent non-executive directors.
Potential Share Price Impact
This announcement is likely to be price sensitive as it involves a major capital raising, supports the company’s growth trajectory, and impacts the shareholding structure. The intended use of proceeds in advancing high-potential drug candidates and commercial operations could significantly enhance future earnings potential and investor confidence.
Disclaimer: This article is for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities. Investors should conduct their own due diligence and seek professional advice before making any investment decisions.
View TRANSTHERA-B Historical chart here
